Etoricoxib and Diclofenac Might Reduce the Risk of Dementia in Patients with Osteoarthritis: A Nation-Wide, Population-Based Retrospective Cohort Study

Dement Geriatr Cogn Disord. 2018;45(5-6):262-271. doi: 10.1159/000485176. Epub 2018 Jun 28.

Abstract

Introduction: This population-based cohort study investigates the association between osteoarthritis (OA) and dementia as well as the connection between NSAIDs and dementia.

Methods: We chose the samples from the Taiwan Longitudinal Health Insurance Database and then divided them into two groups, which were then matched 1: 1 by propensity score. The first group was the OA group that contained patients with newly diagnosed OA and the second group was the non-OA group. We used the χ2 test, Student t test, Kaplan-Meier analysis, and Cox proportional hazard model for different purposes.

Results: The prevalence of dementia in the OA group was higher than that in the non-OA group. The adjusted hazard ratio of the former was 1.42 (95% CI, 1.30-1.54). We also found that etoricoxib and diclofenac might reduce the incidence of dementia.

Conclusion: Patients with OA might have a higher risk of dementia. Both etoricoxib and diclofenac might lower the risk of dementia in patients with OA.

Keywords: Alzheimer disease; Dementia; Diclofenac; Etoricoxib; NSAIDs; Osteoarthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Cohort Studies
  • Dementia / drug therapy*
  • Dementia / epidemiology
  • Diclofenac* / therapeutic use
  • Etoricoxib* / therapeutic use
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Osteoarthritis / complications*
  • Proportional Hazards Models
  • Research Design
  • Retrospective Studies
  • Risk
  • Taiwan / epidemiology

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Diclofenac
  • Etoricoxib